J 2010

Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs

SLABÝ, Ondřej, Milana ŠACHLOVÁ, Markéta BEDNAŘÍKOVÁ, Pavel FABIAN, Marek SVOBODA et. al.

Basic information

Original name

Gene Expression of Somatostatin Receptor 4 Predicts Clinical Outcome of Patients with Metastatic Neuroendocrine Tumors Treated with Somatostatin Analogs

Authors

SLABÝ, Ondřej (203 Czech Republic, guarantor, belonging to the institution), Milana ŠACHLOVÁ (203 Czech Republic, belonging to the institution), Markéta BEDNAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Pavel FABIAN (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic, belonging to the institution), Simona VYTOPILOVÁ (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution) and Rostislav VYZULA (203 Czech Republic, belonging to the institution)

Edition

Cancer Biotherapy and Radiopharmaceuticals, Mary Ann Liebert, 2010, 1084-9785

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.873

RIV identification code

RIV/00216224:14110/10:00051807

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1089/cbr.2009.0708

UT WoS

000277155900014

Keywords in English

carcinoid; neuroendocrine tumors; prognosis; response prediction; somatostatin analogs; somatostatin receptors

Tags

International impact
Změněno: 17/4/2012 11:11, Mgr. Michal Petr

Abstract

V originále

Somatostatin analogs (SSA) are the standard diagnostic and treatment tools in the clinical management of patients with neuroendocrine tumors (NETs) expressing somatostatin receptors (SSTRs). Although symptomatic and biochemical control is obtained with SSA in the majority of functional NETs, antineoplastic effects of SSA are partial and of limited duration. The aim of this study was to quantify expression levels of five SSTR subtypes (SSTR1-SSTR5) and correlate them with the clinical outcomes of patients with NETs who underwent SSA therapy. The expression levels were analyzed using real-time polymerase chain reaction in a series of 22 metastatic NETs with a median time of 10 months on the SSA therapy (range 2-82 months). The median duration of disease stabilization in patients who developed progression (n=14) was 9 months (range 3-92 months). The median survival period for all patients was 44 months (range 3-175 months). According to RECIST criteria, one (5%) partial objective tumor response was obtained, disease stabilization was achieved in 10 (45%) patients, and progressive disease was observed in 11 (50%). Analysis of mRNA expression of the SSTR subtypes showed that SSTR2 and SSTR5 were expressed in all of the studied NETs; SSTR1 and SSTR4 in all but 3 tumors (86%); and SSTR3 in only 10 NETs (49%). Interestingly, our preliminary data suggest that only the levels of SSTR4, though it has the lowest affinity for SSA of all SSTR subtypes, were significantly associated with the stabilization of disease during SSA therapy ( p=0.0357). These levels correlated with time to progression ( p=0.0015) and overall survival ( p=0.0017) in NET patients.
Displayed: 31/10/2024 21:22